The UK and US have secured a key trade agreement that will preserve no import taxes on British medicine exports going into the US market.
Agreement Details of the Pact
In exchange for the tariff guarantee, the UK has agreed to increase funding on pharmaceuticals through the National Health Service (NHS). This move guarantees that duties on these vital exports will remain at nothing for a period of 36 months.
This development follows recent statements to significantly raise import taxes on patented pharmaceutical products, with figures mentioned up to 100%.
"This deal between the Britain bolsters the worldwide climate for new treatments and establishes long-overdue fairness to American-British drug exports," a statement declared.
Economic Significance
Drugs are one of the the United Kingdom's largest goods shipped to the US, which is easily the primary buyer for major British pharmaceutical firms.
Export figures indicate that in the year prior to last September, the UK shipped pharmaceutical products totaling billions to the US. This value made up a significant portion of British export trade in that timeframe.
"This agreement safeguards employment, stimulates investment and facilitates the UK to become a international leader for medical research," a government official commented.
Key UK Commitments
The deal involves several notable pledges from the United Kingdom:
- Revised Affordability Limit: The UK will lift the price threshold at which it considers new medicines to be too expensive by a quarter.
- Higher Drug Budget: There is a target to raise total NHS spending on medicines from 0.3% of Gross Domestic Product to 0.6 percent over the next decade.
- Payback Limit: The sum drug companies must refund to the NHS to prevent overspending will be restricted at 15%. Last year, refunds exceeded 20%.
Industry Background
This agreement follows a long-running row between the sector and the British authorities over drug pricing and regulatory access.
This friction were exacerbated by arguments that American patients were charged a premium for the same drugs than patients in the UK and Europe.
Over the last 18 months, several large pharmaceutical investments in the UK have been paused or abandoned, while multi-billion-dollar investments have been directed toward US facilities.
One official stated that the NHS must increase expenditure on medicines, noting that its spending on drugs had decreased as a proportion of its overall budget over the previous ten-year period.
